290P - Initial outcome of definitive intensity modulated RT in treatment of bone oligometastatic prostate cancer

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Prostate Cancer
Surgical Oncology
Presenter Xin Qi
Citation Annals of Oncology (2016) 27 (suppl_9): ix90-ix93. 10.1093/annonc/mdw584
Authors X. Qi, X. Gao, H.Z. Li, S.B. Qin, M. Zhang, X.M. Li, Q.G. Wang, X.Y. Li, M.W. Ma
  • Radiation Oncology, 1st Hospital Beijing University, 100034 - Beijing/CN



The aim of this study was to evaluate the PSA response rate, biochemical relapse-free survival, and toxicity in bone oligometastatic prostate cancer patients who had undergone definitive intensity modulated radiotherapy (IMRT) for both primary tumor and all metastatic lesions.


From 10/2011 to 9/2015, 22 prostate cancer patients with bone oligometastases (no more than 5 metastatic lesions) were treated. Metastatic lesions were documented by positive bone scan or CT scan or MRI. All patients received IMRT, 40-76Gy in 10-38 fractions (median dose: 60Gy) to metastatic lesions, 45-46Gy to the whole pelvis (for 14 patients, 63.6%) and 72-76Gy to the prostate and seminal vesicles. All patients received MAB using a LHRH agonist or orchiectomy together with an oral anti-androgen before and during RT. After RT, all patients received continuous ADT except one due to cardiovascular disease. Survival was calculated using the Kaplan-Meier method.


A total of 49 bone metastatic lesions were identified in these 22 patients. The median number of metastatic lesions per patient was 2 (range 1-5). 29 (59.1%) lesions were localized in the pelvis, 14 (28.6%) in the spines, 3 (6.1%) in the femurs and 3 (6.1%) in the ribs. The median follow-up was 17 months (range: 2-48 months). The median duration of ADT before RT was 5 months and the median pre-RT PSA was 0.7ng/ml. PSA response rate: 20 patients had a PSA decline 2 months after RT, and 13 of them decreased to 


Our study suggests that definitive IMRT is well tolerated and results in good PSA response and biochemical control in patient with bone oligometastatic prostate cancer. However, the long-term survival outcomes need to be further explored.

Clinical trial indentification

Legal entity responsible for the study





All authors have declared no conflicts of interest.